| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Dermatomyositis (DM) is an immune-mediated disorder that most prominently involves muscle and skin. The loss of tight junction (TJ) of some remaining microvasculature is a hallmark of DM. Firstly, we demonstrated the possibility that sera from DM patients bring apoptosis of endothelium derived from endomysial capillaries. Then, we disclosed that GDNF and bFGF released from human skeletal muscle pericyte cell (HSMPCT) line increase the barrier function of human skeletal muscle microvascular endothelial cell line, TSM15. In addition, we also demonstrated that activated vitamin D strengthen the barrier function of TSM15. These results indicate that bFGF and GDNF, as well as activated vitamin D, might ameliorate the pathophysiology of DM via restoring the fragile barrier of endomysial endothelium.
|
